FDA won't take ac­tion against GLP-1 com­pounders as it re­thinks tirzepatide short­age

The FDA clar­i­fied Thurs­day that it won’t take ac­tion against GLP-1 com­pounders for cer­tain vi­o­la­tions while it reeval­u­ates Eli Lil­ly’s weight loss and di­a­betes drug …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER